Lv1
40 积分 2026-08-02 加入
P1.11.79 A Meta-Analysis on Anti-PD-1/L1 With or Without Anti-VEGF Plus Chemotherapy in EGFR-Mutant or ALK-Rearranged NSCLC Progressing on TKIs
11小时前
求助中
EP.12A.39 MET Point Mutations as the Mechanism of Resistance to EGFR-TKI Therapy: A Case Report of MET H1094Y-Mediated Resistance to Osimertinib Overcome by Capmatinib and a Systematic Review
11小时前
已完结
皖公网安备34019202002308
